OP Asset Management Ltd Acquires New Position in Niagen Bioscience, Inc. $NAGE

OP Asset Management Ltd acquired a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 334,412 shares of the company’s stock, valued at approximately $1,475,000. OP Asset Management Ltd owned approximately 0.42% of Niagen Bioscience at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NAGE. Vanguard Group Inc. acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at approximately $37,522,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth approximately $13,405,000. UBS Group AG acquired a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $11,160,000. Qube Research & Technologies Ltd purchased a new position in Niagen Bioscience in the 3rd quarter valued at approximately $8,175,000. Finally, Millennium Management LLC purchased a new position in Niagen Bioscience in the 3rd quarter valued at approximately $7,224,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group decreased their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Wall Street Zen cut Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. HC Wainwright cut their price target on Niagen Bioscience from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Niagen Bioscience presently has an average rating of “Moderate Buy” and an average price target of $10.50.

Niagen Bioscience Stock Performance

NAGE stock opened at $3.30 on Tuesday. The stock’s 50 day moving average price is $3.91 and its 200 day moving average price is $4.94. The firm has a market cap of $262.81 million, a P/E ratio of 15.71 and a beta of 2.08. Niagen Bioscience, Inc. has a 1 year low of $3.27 and a 1 year high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $31.47 million during the quarter. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%. On average, research analysts predict that Niagen Bioscience, Inc. will post 0.22 earnings per share for the current year.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.